STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the expansion of commercial activities under its multi-year Master Services Agreement (MSA) with Nutrition21 whereby Nutrition21 has transitioned to Applied DNA’s CertainT® platform to secure its IP-protected portfolio of dietary supplement ingredients. Concurrently, the Company received two follow-on orders for a second year of commercial production, the majority of which is expected to be shipped in the current fiscal quarter. The financial terms of the follow-on orders were not disclosed.
Nutrition21, a trusted developer and supplier of novel and clinically substantiated branded ingredients for the nutritional supplement industry, is the first to adopt the platform to protect the IP of its ingredients. Utilizing CertainT, Nutrition21 can certify that its licensees use authentic ingredients and in the proper amounts, and also identify IP infringement by non-licensees. A SigNature® molecular tag is applied to Nutrition21 ingredients to provide evidence of its product dosages in finished products shipped to market. The molecular tag is supported by ongoing quality control testing services for production and high-resolution testing services for products audited in-market. Nutrition21 holds over 100 domestic and international issued and pending patents for its products.
“The expansion of CertainT’s application within Nutrition21 is testament to our platform’s ability to support Nutrition21’s dedication to ensuring confidence in its ingredients portfolio,” said Dr. James A. Hayward, president and CEO, Applied DNA. “With its diverse portfolio of patented health and wellness ingredients, we believe we are in the early stages of an impactful commercial relationship with Nutrition21 and, by proxy, the dietary supplements industry.”
Joe Weiss, President of Nutrition21, stated, “After an extensive search to replace our current marker technology, we have now transitioned to the CertainT platform. Marketing partners and customers of Nutrition21 can rest assured that we will utilize the CertainT platform to protect them against infringers of our intellectual property, and most importantly, assure consumers that they are getting the Nutrition21 ingredients that are listed on their product label.”
The CertainT® platform has three technology pillars (Tag, Test, Track), which allows raw materials and products to be tagged with a unique molecular identifier. This identifier can then be tested for its presence as it travels throughout a global supply chain. All the data points associated to tagging and testing are tracked by uploading to a secure cloud database. The platform can be used across industries such as textiles, cannabis, military, leather, fertilizer, pharmaceuticals, personal care.
About Nutrition21, LLC
Nutrition21 is a trusted developer and supplier of novel and clinically substantiated branded ingredients for the nutritional supplement industry. With a diverse portfolio of patented health and wellness ingredients, Nutrition21 provides ingredient solutions to some of the most successful dietary supplement brands in the marketplace today.
Nutrition21 currently holds over 100 domestic and international issued and pending patents for products with highly marketable claims including: Nitrosigine®, Velositol®, Chromax®, nooLVL®, and Lepidamax®. Innovative Ingredients. Real Results
For more information, please visit: www.Nutrition21.com.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN’, and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly reports on Form 10-Q filed on February 6, 2020, May 14, 2020 and August 6, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.